Clinical Trials Directory

Trials / Completed

CompletedNCT02272517

Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder

An Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study on the Efficacy of Vortioxetine Versus Escitalopram on Cognitive Dysfunction in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
101 (actual)
Sponsor
H. Lundbeck A/S · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.

Conditions

Interventions

TypeNameDescription
DRUGVortioxetine 10-20 mg
DRUGEscitalopram 10-20 mg

Timeline

Start date
2014-12-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2014-10-23
Last updated
2017-02-28

Locations

16 sites across 4 countries: Finland, Germany, Serbia, Slovakia

Source: ClinicalTrials.gov record NCT02272517. Inclusion in this directory is not an endorsement.

Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antid (NCT02272517) · Clinical Trials Directory